Sirtex Medical (ASX:SRX) shares are down slightly today after its radioactive microspheres failed to meet the primary endpoint in a liver cancer trial. The company’s SIR-Spheres Y-90 resin microspheres did not improve survival in patients with advanced hepatocellular carcinoma compared to a group treated with the current standard of care, sorafenib. Data from the 360-patient trial […]
AntriaBio seeks FDA nod for trial of once-weekly insulin
AntriaBio (OTC:ANTB) said today that it filed an investigational new drug application with the FDA for its once-weekly basal insulin. If the Louisville, Colo.-based company wins approval from the FDA, it plans to launch a Phase I clinical trial of AB101 in patients with Type I diabetes. The first-in-human study is slated to evaluate the […]
Novartis, IBM Watson collab to optimize care for patients with advanced breast cancer
Novartis (NYSE:NVS) said today that it inked a deal with IBM Watson Health to optimize care and improve outcomes for patients with advanced breast cancer. The 2 companies plan to develop a “cognitive solution” using real-world patient data and analytics to better understand expected outcomes of breast cancer treatment options and develop personalized treatment plans […]
Cingulate moves controlled-release ADHD drug to human testing
Cingulate Therapeutics said this week that it began a proof-of-concept trial for its controlled-release attention deficit/hyperactivity disorder drug. The 4-week clinical trial is being conducted by its development partner, Bio-Images Drug Delivery. The trial enrolled healthy volunteers to evaluate the pharmacokinetic behavior of CTX-1301, including the body’s absorption, distribution, metabolism and excretion of the drug. […]
Maryland becomes 1st state to pass generic drug price gouging law
Maryland is slated to become the 1st state to pass a law banning “price gouging” by generic pharmaceutical manufacturers. The bill was passed by the Maryland general assembly in April and last month the governor said he would allow the bill to become law without his signature. The bill, which becomes effective on Oct. 1, prohibits […]
Critics allege misleading campaigns, poorly-cited data fueled opioid addiction crisis
The state of Ohio filed a lawsuit against opioid-makers this week, alleging that the companies produced misleading marketing schemes to convince doctors and patients that opioids were not addictive. Ohio isn’t alone – Mississippi and West Virginia have filed similar cases against major players in the pharmaceutical industry. Purdue Pharma, Johnson & Johnson (NYSE:JNJ), Endo […]
BioCorRx partners with virtual reality center for naltrexone implant study
BioCorRx (OTC:BICX) said today that it partnered with the Virtual Reality Medical Center to conduct a study on the company’s long-lasting naltrexone implant. BioCorRx’s recovery program consists of a long-lasting implant that delivers an opioid antagonist, naltrexone, which reduces physical cravings for alcohol and opioids. The recovery service also has a counseling program specifically designed […]
MannKind inks deal to bring inhaled insulin to Brazil
MannKind Corp. (NSDQ:MNKD) said today that the company inked a supply and distribution deal with Biomm for the commercialization of its inhaled insulin, Afrezza, in Brazil. According to the agreement, Biomm will prepare and file the necessary applications for regulatory approval. MannKind will be responsible for manufacturing and supplying Afrezza and Biomm is slated to […]
Cytori launches next-gen Celution cell therapy tech
Cytori Therapeutics (NSDQ:CYTX) said today that the next-gen version of its Celution cell therapy device is available for pre-order and that the 1st shipments will start in the 3rd quarter of 2017. The San Diego-based company’s Celution system automates the extraction and concentration of autologous, clinical-grade adipose-derived regenerative cells. The next-gen Celution tech includes new […]
Philips, Illumina to launch precision medicine cancer program with Navican
Royal Philips (NYSE:PHG) and Intermountain Healthcare company Navican inked an agreement today to launch a precision health informatics solution aimed at improving outcomes for late stage cancer patients. The program is slated to leverage Navican‘s TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics platform, which uses Illumina‘s next-gen genomic sequencing technologies. At Utah-based Intermountain Healthcare’s […]